Redwood Wealth Management Group LLC Purchases 20 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Redwood Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 497 shares of the biopharmaceutical company’s stock after acquiring an additional 20 shares during the period. Redwood Wealth Management Group LLC’s holdings in Regeneron Pharmaceuticals were worth $354,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Ninety One UK Ltd increased its position in Regeneron Pharmaceuticals by 14.4% during the fourth quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock valued at $55,565,000 after acquiring an additional 9,820 shares during the last quarter. E. Ohman J or Asset Management AB increased its position in Regeneron Pharmaceuticals by 12.2% during the fourth quarter. E. Ohman J or Asset Management AB now owns 4,970 shares of the biopharmaceutical company’s stock valued at $3,540,000 after acquiring an additional 540 shares during the last quarter. Calamos Advisors LLC increased its position in Regeneron Pharmaceuticals by 86.7% during the fourth quarter. Calamos Advisors LLC now owns 22,658 shares of the biopharmaceutical company’s stock valued at $16,140,000 after acquiring an additional 10,523 shares during the last quarter. Columbus Macro LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $232,000. Finally, abrdn plc increased its position in Regeneron Pharmaceuticals by 0.9% during the fourth quarter. abrdn plc now owns 188,451 shares of the biopharmaceutical company’s stock valued at $133,303,000 after acquiring an additional 1,740 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $983.65.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $697.05 on Wednesday. The firm has a market capitalization of $76.60 billion, a P/E ratio of 17.25, a PEG ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average price of $719.16 and a 200 day moving average price of $918.90. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $11.86 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.